

## Alligator Bioscience AB: Correction regarding MAR marking

The press release as of October 21, 2020 regarding the Interim report January – September 2021 incorrectly contained a so-called MAR marking. This was not the company's intention, as the information is not to be regarded as inside information.

**For further information, please contact:**

Julie Silber, Investor Relations

Phone: +46 46-540 82 23

E-mail: [jur@alligatorbioscience.com](mailto:jur@alligatorbioscience.com)

**About Alligator Bioscience**

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed molecule based on its proprietary Neo-X-Prime™ technology platform with MacroGenics Inc. Outlicensed programs include AC101 in clinical development by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX). Alligator is headquartered in Lund, Sweden. For more information, please visit <http://www.alligatorbioscience.com>.